Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Academic Article


  • Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction. Copyright © 2012 by Lippincott Williams & Wilkins.
  • Digital Object Identifier (doi)

    Author List

  • Vinikoor MJ; Cope A; Gay CL; Ferrari G; McGee KS; Kuruc JD; Lennox JL; Margolis DM; Hicks CB; Eron JJ
  • Start Page

  • 505
  • End Page

  • 508
  • Volume

  • 62
  • Issue

  • 5